Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?

Joint Bone Spine

Volumn 77, Issue 1, 2010, Pages 4-5

  Costedoat Chalumeau, Nathalie ^a   Leroux, Gaelle ^a   Piette, Jean Charles ^a   Amoura, Zahir ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Flare; Hydroxychloroquine; Systemic lupus erythematosus; Therapeutic drug monitoring

Indexed keywords

HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG HALF LIFE; DRUG WITHDRAWAL; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETINOPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT CONTRAINDICATION;

ANTIRHEUMATIC AGENTS; DRUG MONITORING; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK ASSESSMENT;

EID: 73649102100     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.09.007     Document Type: Editorial

References (22)

1. Burt R.K., Traynor A., Statkute L., et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295 5 (2006) 527-535
2. Petri M., Kim M.Y., Kalunian K.C., et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353 24 (2005) 2550-2558
3. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324(3):150-4.
4. Kasitanon N., Fine D.M., Haas M., et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15 6 (2006) 366-370
5. James J.A., Kim-Howard X.R., Bruner B.F., et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16 6 (2007) 401-409
6. Wasko M.C., Hubert H.B., Lingala V.B., et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298 2 (2007) 187-193
7. Kaiser R., Cleveland C.M., and Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 68 2 (2009) 238-241
8. Mok C.C., Mak A., and Ma K.M. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14 2 (2005) 106-112
9. Ruiz-Irastorza G., Ugarte A., Egurbide M.V., et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 66 6 (2007) 815-817
10. Munro R., Morrison E., McDonald A.G., et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 56 6 (1997) 374-377
11. Fessler B.J., Alarcon G.S., McGwin Jr. G., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52 5 (2005) 1473-1480
12. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15 9 (2006) 577-583
13. Alarcon G.S., McGwin Jr. G., Bertoli A.M., et al. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. Data from lumina, a multiethnic us cohort (LUMINA L). Ann Rheum Dis 66 9 (2007) 1168-1172
14. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54 10 (2006) 3284-3290
15. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., et al. Very low blood Hydroxychloroquine concentrations as an objective marker of poor adherence to treatment in systemic lupus erythematosus. Ann Rheum Dis 66 6 (2007) 821-824
16. Costedoat-Chalumeau N., Amoura Z., Duhaut P., et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 48 11 (2003) 3207-3211
17. Marmor M.F. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum 48 6 (2003) 1764
18. Levy G.D., Munz S.J., Paschal J., et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 40 8 (1997) 1482-1486
19. Marmor M.F., Carr R.E., Easterbrook M., et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109 7 (2002) 1377-1382
20. Rigaudiere F., Ingster-Moati I., Hache J.C., et al. Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment. J Fr Ophtalmol 27 2 (2004) 191-199
21. Stein M., Bell M.J., and Ang L.C. Hydroxychloroquine neuromyotoxicity. J Rheumatol 27 12 (2000) 2927-2931
22. Costedoat-Chalumeau N., Hulot J.S., Amoura Z., et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 107 2 (2006) 73-80